Scientists have successfully engineered tobacco plants to produce five potent psychedelic compounds – psilocin, psilocybin, DMT, bufotenin, and 5-methoxy-DMT – that are typically sourced from mushrooms, plants, and even animal secretions like the Colorado river toad. This breakthrough offers a potentially simpler and more sustainable method for producing these substances, primarily for research and future pharmaceutical applications.
The Science Behind the Breakthrough
The research team, led by Asaph Aharoni at the Weizmann Institute of Science in Israel, employed a technique called agroinfiltration. This method uses bacteria to temporarily introduce genes from other organisms into the tobacco plants (Nicotiana benthamiana ). The plants then synthesize proteins based on these introduced genes, but the DNA isn’t permanently integrated into the plant’s genome, preventing unintended inheritance.
Adding just nine genes enabled the plants to produce all five psychedelic compounds. Currently, these substances are either extracted from natural sources (which can strain threatened populations) or synthesized chemically, both of which are less efficient than this new method.
Why This Matters: The Rise of Psychedelic Medicine
The growing interest in psychedelic compounds for therapeutic purposes, including treatment-resistant depression and PTSD, is driving demand for more reliable and scalable production methods. Current sourcing practices risk overexploitation of wild populations, making plant-based manufacturing an attractive alternative.
The fact that this can be done in tobacco plants is significant because tobacco is easily cultivated in controlled environments like greenhouses, reducing external pressures on wild resources. This also opens the door for future pharmaceutical farming (“pharming”), where crops are genetically modified to produce drugs.
The Bigger Picture: “Pharming” and Green Factories
The concept of using plants as “green factories” for drug production isn’t new. Plant-derived protein drugs have been approved in the US since 2012, and research in this field dates back to at least 2002 when maize was engineered to produce a pharmaceutical protein. More recently, in 2022, tobacco plants were used to synthesize cocaine, demonstrating their potential for producing even illicit compounds.
Rupert Fray at the University of Nottingham highlights that roughly 25% of prescription drugs are already plant-derived, and there are huge opportunities to expand this practice. The ability to manufacture complex molecules in plants proves an understanding of biochemical pathways, which is essential for further research.
“If you want to understand something, you’ve got to be able to build something, so showing that you can make it in tobacco plants is useful,” says Fray.
The researchers acknowledge the ethical implications of genetically modifying plants to produce recreational drugs and have taken precautions to prevent the engineered traits from becoming inheritable. Despite this, the technology’s potential raises questions about access, regulation, and the future of psychedelic production.
This development marks a significant step towards more efficient and sustainable drug manufacturing, but also underscores the need for careful consideration of its broader implications.
